primari
immunodefici
disord
pid
monogen
defect
affect
innat
andor
adapt
immun
system
patient
increas
risk
wide
rang
manifest
includ
autoimmun
immun
dysregul
malign
infecti
complic
commonest
histor
pid
patient
use
die
recognit
infect
due
lack
effect
measur
either
prevent
treat
advanc
public
health
discoveri
antimicrobi
agent
made
diagnosi
pid
possibl
although
therapeut
intervent
like
intraven
immunoglobulin
hematopoiet
stem
cell
transplant
help
decreas
morbid
mortal
physician
care
pid
patient
frequent
struggl
treat
infect
usual
recurr
chronic
sever
frequent
caus
opportunist
organ
among
microb
virus
pid
patient
challeng
increas
risk
mortal
may
predispos
malign
pid
may
also
lead
reduc
clearanc
prolong
shed
certain
virus
like
rhinoviru
polioviru
pid
predispos
wide
spectrum
viral
infect
certain
diseas
enhanc
vulner
specif
viral
infect
wherea
risk
viral
infect
pid
wellestablish
recent
review
awar
report
character
infect
larg
cohort
patient
differ
type
pid
report
present
frequenc
spectrum
viral
infect
primari
immunodefici
children
kuwait
januari
decemb
data
obtain
kuwait
nation
primari
immunodefici
disord
registri
knpidr
approv
research
ethic
committe
ministri
health
kuwait
kuwait
univers
health
scienc
center
ethic
committe
accord
declar
helsinki
patient
follow
prospect
classifi
accord
intern
union
immunolog
societi
primari
immunodefici
diseas
committe
report
inborn
error
immun
secondari
immunodefici
drug
induc
hiv
induc
immunodefici
associ
metabol
rule
obtain
detail
histori
perform
appropri
test
disord
suspect
clinic
diagnosi
base
standard
care
depend
patient
sign
symptom
support
laboratori
andor
radiolog
find
exampl
patient
diagnos
pneumonia
present
respiratori
sign
symptom
associ
radiolog
find
diagnosi
herp
simplex
viru
hsv
kerat
stomat
wart
caus
human
papilloma
viru
hpv
varicellazost
viru
vzv
molluscum
contagiosum
infect
base
clinic
evalu
inhous
polymeras
chain
reaction
pcr
use
initi
test
cytomegaloviru
cmv
viru
ebv
herpesviru
adenoviru
respiratori
gastrointestin
virus
replac
later
commerci
kit
indic
patient
gastrointestin
manifest
stool
colon
sampl
collect
deep
nasopharyng
aspir
bronchoalveolar
lavag
sampl
collect
patient
respiratori
manifest
use
steril
nylon
flock
swab
bronchoscopi
place
viral
transport
medium
serum
cerebrospin
fluid
sampl
collect
viral
infect
requir
sampl
label
transport
earliest
virolog
laboratori
faculti
medicin
kuwait
univers
daytoday
routin
screen
viral
infect
storag
viral
nucleic
acid
sampl
extract
use
autom
magna
pure
lc
system
roch
diagnost
system
branchburg
nj
multiplex
realtim
onestep
revers
transcript
pcr
rtpcr
fasttrack
diagnost
ftd
respiratori
pathogen
assay
fasttrack
diagnost
ltd
sliema
malta
perform
lightcycl
rtpcr
thermocycl
roch
meylan
franc
detect
virus
includ
influenza
flu
influenza
subtyp
human
rhinoviru
hrv
influenza
b
flu
b
human
coronavirus
human
parainfluenza
virus
human
bocaviru
hbov
human
metapneumoviru
hmpv
ab
respiratori
syncyti
viru
rsvab
respiratori
human
adenoviru
hadv
enteroviru
ev
human
parechoviru
hpev
viral
gastroenter
ge
kit
fasttrack
diagnost
ltd
sliema
malta
use
detect
rotaviru
adenoviru
astroviru
noroviru
sapoviru
stool
sampl
homogen
prior
extract
mg
aliquot
suspend
ml
nucleasefre
water
ml
stool
transport
recoveri
buffer
roch
diagnost
meylan
franc
suspens
immedi
clarifi
centrifug
g
min
accord
manufactur
instruct
rtpcr
perform
nucleic
acid
use
lightcycl
rtpcr
thermocycl
roch
meylan
franc
cmv
ebv
enteroviru
hadv
detect
perform
serum
stoolcolon
respiratori
csf
sampl
tib
molbiol
berlin
germani
amplif
perform
accord
manufactur
instruct
lightcycl
rtpcr
thermocycl
roch
meylan
franc
presenc
polioviru
rna
clinic
sampl
confirm
onestep
revers
transcriptionpcr
follow
direct
sequenc
pcr
product
describ
previous
data
process
use
ibm
spss
version
ibm
corpor
armonk
ny
usa
pearson
chisquar
test
use
assess
associ
two
categor
variabl
nonparametr
mannwhitney
utest
appli
assess
whether
patient
age
onset
symptom
pid
signific
effect
risk
viral
infect
effect
age
onset
assess
quantit
qualit
variabl
divid
group
month
p
use
cutoff
level
statist
signific
total
pid
children
male
femal
regist
knpidr
studi
period
distribut
patient
accord
pid
categori
immunodefici
affect
cellular
humor
immun
patient
combin
immunodefici
associ
syndrom
featur
patient
predominantli
antibodi
defici
patient
diseas
immun
dysregul
patient
congenit
defect
phagocyt
number
function
patient
autoinflammatori
disord
patient
complement
defici
patient
patient
defect
innat
immun
regist
seventyon
patient
treat
hematopoiet
stem
cell
transplant
hsct
receiv
intraven
immunoglobulin
import
mention
report
viral
infect
occur
prior
hsct
patient
receiv
treatment
overal
infecti
complic
affect
patient
viral
infect
affect
patient
regist
patient
fortyf
patient
develop
viral
infect
caus
least
organ
mostli
categori
immunodefici
affect
cellular
humor
immun
patient
among
patient
affect
three
viral
infect
statist
signific
associ
viral
infect
pid
categori
exclud
patient
belong
congenit
defect
phagocyt
number
function
autoinflammatori
disord
complement
defici
due
low
number
p
tabl
howev
statist
signific
associ
viral
infect
gender
p
patient
onset
age
assess
quantit
qualit
variabl
pvalu
respect
total
viral
infect
studi
period
detect
time
pid
diagnosi
document
establish
diagnosi
caus
infect
cmv
adenoviru
ebv
enterovirus
hsv
hpv
vzv
rhinoviru
molluscum
contagiosum
figur
noroviru
parainfluenza
viru
viru
rotaviru
rsv
sapoviru
corona
viru
patient
sever
combin
immunodefici
present
myocard
caus
polioviru
type
two
patient
sever
combin
immunodefici
mhc
ii
defici
prolong
excret
polioviru
type
stool
detail
viral
infect
present
tabl
figur
show
number
patient
affect
differ
virus
accord
pid
categori
promin
find
cmv
parainfluenza
infect
common
group
immunodefici
affect
cellular
humor
immun
ebv
hpv
common
immun
dysregul
group
combin
immunodefici
associ
syndrom
featur
respect
common
present
viremia
follow
pneumonia
skin
infect
tabl
common
caus
viremia
cmv
follow
adenoviru
ebv
common
organ
caus
pneumonia
cmv
follow
rhinoviru
parainfluenza
tabl
death
among
regist
patient
caus
viral
infect
follow
cmv
pneumonia
patient
enteroviru
sepsi
patient
rsv
pneumonia
patient
myocard
patient
adenoviru
sepsi
patient
complic
liver
failur
current
studi
present
characterist
viral
infect
larg
cohort
pid
children
follow
prospect
period
year
viral
infect
affect
regist
patient
mani
affect
viru
patient
affect
rang
viral
organ
cmv
adenoviru
ebv
culprit
almost
half
case
high
frequenc
cmv
infect
cohort
explain
fact
case
affect
combin
immunodefici
patient
defect
extrem
suscept
progress
infect
cmv
find
cmv
parainfluenza
infect
common
group
immunodefici
affect
cellular
humor
immun
document
previous
observ
ebv
common
immun
dysregul
group
specif
trigger
hlh
also
welldocu
found
patient
defici
particularli
predispos
mucocutan
viral
infect
like
molluscum
contagiosum
hsv
infect
probabl
sinc
import
regul
actin
cytoskeleton
critic
cell
migrat
collagendens
tissu
henc
play
import
antivir
immun
skin
present
cohort
patient
character
high
frequenc
combin
immunodefici
sever
higher
predisposit
viral
infect
compar
pid
categori
anoth
promin
featur
cohort
none
regist
patient
suffer
increas
suscept
specif
viral
infect
exampl
diseas
trif
defici
predispos
enceph
epidermodysplasia
verruciformi
defici
predispos
hpv
import
stress
physician
awar
pid
consid
patient
sever
recurr
viral
infect
importantli
awar
mani
pid
result
poor
antibodi
respons
henc
serolog
test
avoid
test
patient
infecti
complic
antigen
detect
method
use
instead
health
care
provid
also
awar
recommend
live
viral
vaccin
immunodefici
patient
close
contact
live
vaccin
chicken
pox
measl
mump
rubella
mmr
rotaviru
yellow
fever
oral
polio
influenza
nasal
spray
avoid
certain
type
pid
furthermor
infant
born
famili
suspici
histori
pid
avoid
live
viral
bacteri
vaccin
pid
rule
histor
oral
polio
vaccin
opv
form
use
vaccin
schedul
kuwait
sinc
first
dose
opv
given
age
month
replac
inactiv
formul
fortun
patient
cohort
diagnos
defici
develop
opv
relat
complic
ie
myocard
two
patient
cid
prolong
excret
polioviru
type
stool
unfortun
stool
surveil
program
pid
patient
vaccin
deriv
polio
viru
avail
countri
present
studi
limit
sinc
determin
true
burden
viral
infect
pid
could
establish
document
number
admiss
intens
care
unit
type
care
provid
like
mechan
ventil
use
inotrop
admiss
import
variabl
consid
number
viral
infect
reactiv
number
admiss
hospit
length
stay
durat
use
antivir
treatment
howev
import
strength
studi
patient
follow
prospect
clinic
immunologist
anoth
import
strength
studi
patient
diagnos
molecular
level
may
help
determin
genotypephenotyp
correl
yet
collabor
effort
need
collect
bigger
number
patient
viral
infect
pid
treat
aggress
appropri
antivir
medic
definit
treatment
like
hsct
possibl
sinc
failur
erad
viral
pathogen
creat
inflammatori
environ
promot
cell
surviv
prolifer
may
predispos
malign
innov
treatment
like
virusspecif
cell
explor
improv
clinic
outcom
group
patient
dataset
gener
studi
includ
manuscript
andor
supplementari
file
data
obtain
kuwait
nation
primari
immunodefici
disord
registri
knpidr
approv
research
ethic
committe
ministri
health
kuwait
kuwait
univers
health
scienc
center
ethic
committe
accord
declar
helsinki
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
